Commentary|Videos|October 21, 2025
Pinpointing Pivotal Prostate Cancer Data With Drs Agarwal and Shore
Neeraj Agarwal, MD, FASCO, and Neal Shore, MD, FACS, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in prostate cancer presented during the 2025 ESMO Congress.
Advertisement
Neeraj Agarwal, MD, FASCO, of Huntsman Cancer Institute, and Neal Shore, MD, FACS, of Carolina Urologic Research Center, sit down with Chandler Park, MD, FACP, of Norton Cancer Institute, to discuss the latest abstracts in prostate cancer presented during the 2025 ESMO Congress.
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
lan M. Thompson Jr., MD, discusses the potential role of 5-ARIs for the treatment of patients with prostate cancer.
Dostarlimab monotherapy produced a 27% response rate in PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma
Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.
Adding an IL-15 receptor superagonist to a vaccine plus bintrafusp alfa produced clinical responses in pMMR CRPC.
Darlifarnib plus cabozantinib showed durable responses and manageable safety in cabozantinib-naive advanced clear cell RCC.
The FDA has approved lutetium Lu 177 vipivotide tetraxetan plus an ARPI for PSMA-positive metastatic hormone-sensitive prostate cancer.
A post-hoc analysis of LITESPARK-005 found that higher baseline and improved on-treatment QOL scores tracked with lower risk of disease progression and death.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer
2
FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
3
The OncFive: Top Oncology Articles for the Week of 8/2
4
Five Under 5: Top Oncology Videos for the Week of 8/2
5